Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Free Cash Flow (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of Free Cash Flow data on record, last reported at $3.2 million in Q2 2025.

  • For Q2 2025, Free Cash Flow rose 176.54% year-over-year to $3.2 million; the TTM value through May 2025 reached -$13.6 million, up 24.9%, while the annual FY2025 figure was -$13.6 million, 24.9% up from the prior year.
  • Free Cash Flow reached $3.2 million in Q2 2025 per LFCR's latest filing, up from -$4.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $5.1 million in Q2 2023 and bottomed at -$18.8 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$4.8 million, with a median of -$4.3 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: crashed 652.18% in 2022, then skyrocketed 317.29% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at $1.1 million in 2021, then plummeted by 652.18% to -$6.2 million in 2022, then soared by 47.01% to -$3.3 million in 2023, then plummeted by 156.18% to -$8.4 million in 2024, then soared by 138.61% to $3.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $3.2 million in Q2 2025, -$4.4 million in Q1 2025, and -$8.4 million in Q4 2024.